Increased Hospitalization and Mortality from COVID-19 in Prostate Cancer Patients

Chakravarty, Dimple; Ratnani, Parita; Sobotka, Stanislaw; Lundon, Dara; Wiklund, Peter; Nair, Sujit S.; Tewari, Ashutosh

doi:10.3390/cancers13071630

Cited by 19 publications

(16 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Finally, multiomic targets including disease- and stage-specific cell-free nucleic acid patterns are highly recommended for secondary PCa care [ 27 ]. To this end, PCa secondary care is highly relevant for protection of these patients against co-morbidities such as COVID-19 co-diagnosis: PCa patients are strongly predisposed to increased hospitalisation and mortality rates, for example, compared to patients with non-prostate genitourinary malignancies infected with COVID-19 [ 28 ].…”

Section: Risk Assessment Patient Stratification and Targeted Preventi...mentioning

confidence: 99%

Prostate cancer treatment costs increase more rapidly than for any other cancer—how to reverse the trend?

et al. 2022

View full text Add to dashboard Cite

According to GLOBOCAN, about 1.41 million new prostate cancer (PCa) cases were registered in the year 2020 globally. The corresponding socio-economic burden is enormous. Anti-cancer mRNA-based therapy is a promising approach, the principle of which is currently applied for anti-COVID-19 vaccination, undergoing a detailed investigation in populations considering its short- and long-term effectiveness and potential side effects. Pragmatically considered, it will take years or even decades to make mRNA therapy working for any type of cancers, and if possible, for individual malignancy sub-types which are many specifically for the PCa. Actually, the costs of treating PCa are increasing more rapidly than those of any other cancer. The trend has to be reversed now, not in a couple of years. In general, two main components are making currently applied reactive (management of clinically manifested disease) PCa treatment particularly expensive. On one hand, it is rapidly increasing incidence of the disease and metastatic PCa as its subtype. To this end, rapidly increasing PCa incidence rates in young and middle-aged male sub-populations should be taken into account as a long-term contributor to the metastatic disease potentially developed later on in life. On the other hand, patient stratification to differentiate between non-metastatic PCa (no need for an extensive and costly treatment) and particularly aggressive cancer subtypes requiring personalised treatment algorithms is challenging. Considering current statistics, it becomes obvious that reactive medicine got at its limit in PCa management. Multi-professional expertise is unavoidable to create and implement anti-PCa programmes in the population. In our strategic paper, we exemplify challenging PCa management by providing detailed expert recommendations for primary (health risk assessment), secondary (prediction and prevention of metastatic disease in PCa) and tertiary (making palliative care to the management of chronic disease) care in the framework of predictive, preventive and personalised medicine.

show abstract

Section: Risk Assessment Patient Stratification and Targeted Preventi...mentioning

confidence: 99%

Prostate cancer treatment costs increase more rapidly than for any other cancer—how to reverse the trend?

et al. 2022

View full text Add to dashboard Cite

show abstract

“…121 , 122 , 123 , 124 , 125 , 126 Another study showed that prostate cancer patients with COVID‐19 had higher rates of hospitalization and mortality compared with non‐prostate genitourinary cancer patients with COVID‐19. 127 …”

Section: Crucial Role Of Sex Hormones In Modulating the Immune Respon...mentioning

confidence: 99%

The immune response to COVID‐19: Does sex matter?

Sepand

Bigdelou

et al. 2022

Immunology

View full text Add to dashboard Cite

The coronavirus disease 2019 (COVID‐19) pandemic has created unprecedented challenges worldwide. Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) causes COVID‐19 and has a complex interaction with the immune system, including growing evidence of sex‐specific differences in the immune response. Sex‐disaggregated analyses of epidemiological data indicate that males experience more severe symptoms and suffer higher mortality from COVID‐19 than females. Many behavioural risk factors and biological factors may contribute to the different immune response. This review examines the immune response to SARS‐CoV‐2 infection in the context of sex, with emphasis on potential biological mechanisms explaining differences in clinical outcomes. Understanding sex differences in the pathophysiology of SARS‐CoV‐2 infection will help promote the development of specific strategies to manage the disease.

show abstract

“…On the one hand, mPC patients may require extra care because of the elevated risk of infection from an immune-suppressive state, which may be the result of treatment-related AEs, reduced physical performance status, and old age [ 55 ]. Studies suggested that among COVID-positive cancer patients, those with PC were more likely to be hospitalized or die than those with non-prostate genitourinary malignancies [ 56 ]. On the other hand, physical contact may need to be minimised to reduce the risk of transmission, such as in terms of postponing surgeries and limiting in-person consultations [ 57 ].…”

Section: Covid-19 Considerationsmentioning

confidence: 99%

Ethnic Pharmacogenomic Differences in the Management of Asian Patients with Metastatic Prostate Cancer

Poon

Chan

et al. 2022

Cancers

View full text Add to dashboard Cite

Progression to metastatic disease occurs in about half of all men who develop prostate cancer (PC), one of the most common cancers in men worldwide. Androgen deprivation therapy has been the mainstay therapy for patients with metastatic PC (mPC) since the 1940s. In the last decade, there has been unprecedented advancement in systemic therapies, e.g., taxane, androgen-signalling pathway inhibitors, and biomarker-driven targeted therapies for various stages of disease, resulting in overall survival improvement. Adding to ongoing controversies over how best to treat these patients is the recognition that ethnicity may influence prognosis and outcomes. This review discusses recent evidence for the impacts of Asian ethnicity specifically, which includes environmental, sociocultural, and genetic factors, on the approach to pharmacological management of mPC. Clear inter-ethnic differences in drug tolerability, serious adverse events (AEs), and genetic heterogeneity must all be considered when dosing and scheduling for treatment, as well as designing future precision studies in PC.

show abstract

Increased Hospitalization and Mortality from COVID-19 in Prostate Cancer Patients

Cited by 19 publications

References 37 publications

Prostate cancer treatment costs increase more rapidly than for any other cancer—how to reverse the trend?

Prostate cancer treatment costs increase more rapidly than for any other cancer—how to reverse the trend?

The immune response to COVID‐19: Does sex matter?

Ethnic Pharmacogenomic Differences in the Management of Asian Patients with Metastatic Prostate Cancer

Contact Info

Product

Resources

About